{"id":"non-biologic-dmards","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Non-biologic disease-modifying antirheumatic drugs (DMARDs) include conventional synthetic agents such as methotrexate, sulfasalazine, and leflunomide that work through various immunosuppressive pathways to inhibit T-cell proliferation, reduce cytokine production, and modulate immune responses. These agents target intracellular signaling pathways and metabolic processes critical to immune cell activation, thereby reducing joint inflammation and preventing structural damage in rheumatoid arthritis and related autoimmune diseases.","oneSentence":"Non-biologic DMARDs are small-molecule drugs that suppress the immune system to reduce inflammation and slow disease progression in rheumatoid arthritis and other autoimmune conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:22.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other autoimmune inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07417995","phase":"","title":"A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Royal United Hospitals Bath NHS Foundation Trust","startDate":"2026-03","conditions":"Psoriasis Arthritis","enrollment":400},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT05543642","phase":"PHASE4","title":"The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-10-11","conditions":"Rheumatic Diseases","enrollment":129},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT06945666","phase":"PHASE4","title":"A Study of Iguratimod in Combination With Tofacitinib in RA Patients","status":"NOT_YET_RECRUITING","sponsor":"Jie Chang","startDate":"2025-08-01","conditions":"Rheumatoid Arthritis (RA","enrollment":200},{"nctId":"NCT01247766","phase":"","title":"Safety Study of Abatacept to Treat Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12-31","conditions":"Rheumatoid Arthritis","enrollment":6367},{"nctId":"NCT03531073","phase":"","title":"Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-04-18","conditions":"Psoriatic Arthritis","enrollment":446},{"nctId":"NCT05291819","phase":"NA","title":"Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2022-03-14","conditions":"Psoriatic Arthritis","enrollment":202},{"nctId":"NCT06417138","phase":"","title":"Comparative Effectiveness of Different Drugs Used to tr€at Patients in Rheumatoid Arthritis Saudi Database (RASD)\"","status":"RECRUITING","sponsor":"Umm Al-Qura University","startDate":"2023-12-15","conditions":"Rheumatoid Arthritis RA","enrollment":800},{"nctId":"NCT05545020","phase":"PHASE2, PHASE3","title":"Trivalent Chromium Treatment for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-12-25","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT01844518","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-30","conditions":"Active Polyarticular Juvenile Idiopathic Arthritis","enrollment":219},{"nctId":"NCT05767801","phase":"","title":"Synovial Tissue and Blood Signature of Rheumatoid Arthritis Patients With Disease Flare After Treatment Discontinuation for Sustained Remission.","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-11-15","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT05683769","phase":"","title":"microRNA in Erosive Hand Osteoarthritis and Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Siena","startDate":"2018-09-01","conditions":"Erosive Osteoarthritis, Psoriatic Arthritis","enrollment":150},{"nctId":"NCT04434885","phase":"","title":"Axial Involvement in Psoriatic Arthritis Cohort","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2021-07-01","conditions":"Psoriatic Arthritis","enrollment":400},{"nctId":"NCT01146652","phase":"PHASE3","title":"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06-21","conditions":"Rheumatoid Arthritis","enrollment":2023},{"nctId":"NCT01490450","phase":"PHASE2","title":"Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-12","conditions":"Arthritis, Psoriatic","enrollment":165},{"nctId":"NCT03011242","phase":"","title":"DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2017-01-11","conditions":"Psoriatic Arthritis","enrollment":47},{"nctId":"NCT03964649","phase":"","title":"Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-01","conditions":"Arthritis, Rheumatoid","enrollment":7308},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03797872","phase":"PHASE4","title":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-17","conditions":"Psoriatic Arthritis","enrollment":1},{"nctId":"NCT01387802","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06-29","conditions":"Ankylosing Spondylitis","enrollment":722},{"nctId":"NCT01559038","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02-16","conditions":"Psoriatic Arthritis","enrollment":483},{"nctId":"NCT01095393","phase":"","title":"National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09-01","conditions":"Rheumatoid Arthritis","enrollment":12500},{"nctId":"NCT02584855","phase":"PHASE3","title":"A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-09-14","conditions":"Psoriatic Arthritis","enrollment":394},{"nctId":"NCT03330769","phase":"","title":"Ultrasound in Psoriatic Arthritis Treatment","status":"UNKNOWN","sponsor":"University of Cagliari","startDate":"2017-02-03","conditions":"Arthritis, Psoriatic, Ultrasonography, Minimal Disease, Residual","enrollment":250},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139},{"nctId":"NCT03327454","phase":"","title":"Benepali® PEN Patient Satisfaction Survey","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-08-10","conditions":"Rheumatoid Arthritis, Spondyloarthropathies","enrollment":500},{"nctId":"NCT01407419","phase":"NA","title":"The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population","status":"COMPLETED","sponsor":"CorEvitas","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":538},{"nctId":"NCT02832297","phase":"NA","title":"Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care","status":"UNKNOWN","sponsor":"Crescendo Bioscience","startDate":"2016-06","conditions":"Arthritis, Rheumatoid","enrollment":318},{"nctId":"NCT02046616","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-28","conditions":"Rheumatoid Arthritis","enrollment":133},{"nctId":"NCT01034397","phase":"PHASE4","title":"A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT01063062","phase":"PHASE3","title":"A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-28","conditions":"Rheumatoid Arthritis","enrollment":107},{"nctId":"NCT00810277","phase":"PHASE3","title":"A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-30","conditions":"Rheumatoid Arthritis","enrollment":14},{"nctId":"NCT01362062","phase":"","title":"Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10-26","conditions":"Rheumatoid Arthritis","enrollment":110},{"nctId":"NCT01941940","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-05","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT02019901","phase":"NA","title":"GotNet Study, The Gothenburg Nurse-led Tight Control Study","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT00443651","phase":"PHASE3","title":"A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-01","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT00975130","phase":"PHASE3","title":"Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":3366},{"nctId":"NCT03082573","phase":"PHASE4","title":"Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel","status":"UNKNOWN","sponsor":"Iraj Sabahi Research Inc.","startDate":"2017-03-03","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT01088321","phase":"","title":"Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-03","conditions":"Rheumatoid Arthritis","enrollment":81332},{"nctId":"NCT01617005","phase":"","title":"A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT02011334","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07","conditions":"Rheumatoid Arthritis","enrollment":285},{"nctId":"NCT01878318","phase":"PHASE4","title":"A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01149057","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":145},{"nctId":"NCT01578850","phase":"PHASE4","title":"Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":491},{"nctId":"NCT01194414","phase":"PHASE3","title":"A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":1262},{"nctId":"NCT02784808","phase":"","title":"Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2000-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":4557},{"nctId":"NCT01717846","phase":"PHASE4","title":"Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2012-12","conditions":"Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis","enrollment":""},{"nctId":"NCT01245439","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":65},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT00750880","phase":"PHASE3","title":"An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":1681},{"nctId":"NCT01106079","phase":"PHASE3","title":"TIght COntrol of Psoriatic Arthritis","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2008-05","conditions":"Psoriatic Arthritis","enrollment":206},{"nctId":"NCT01254331","phase":"PHASE3","title":"An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":51},{"nctId":"NCT01195272","phase":"PHASE4","title":"A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-08","conditions":"Rheumatoid Arthritis","enrollment":21},{"nctId":"NCT01251120","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Rheumatoid Arthritis","enrollment":2},{"nctId":"NCT00883753","phase":"PHASE3","title":"An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":934},{"nctId":"NCT01001182","phase":"","title":"Health Outcomes in Rheumatoid Arthritis in Greece","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Rheumatoid Arthritis","enrollment":210},{"nctId":"NCT01089023","phase":"PHASE4","title":"A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":95},{"nctId":"NCT01353859","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":39},{"nctId":"NCT01835613","phase":"PHASE4","title":"Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.","status":"UNKNOWN","sponsor":"Osservatorio Epidemiologico GISEA","startDate":"2013-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":150},{"nctId":"NCT00891020","phase":"PHASE3","title":"A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-05","conditions":"Rheumatoid Arthritis","enrollment":886},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT00048932","phase":"PHASE3","title":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1795}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Non-Biologic DMARDs","genericName":"Non-Biologic DMARDs","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Non-biologic DMARDs are small-molecule drugs that suppress the immune system to reduce inflammation and slow disease progression in rheumatoid arthritis and other autoimmune conditions. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}